Clinical Trial Update: A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 study evaluating safety and immune response of Moderna's RSV vaccine mRNA-1345 co-administered with Fluzone High-Dose in adults aged 65 and older; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus

Drugs mentioned

• Fluzone High-Dose (Influenza vaccine, high-dose)
• mRNA-1345

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Respiratory Syncytial Virus | Phase 3 | Status: COMPLETED | Results posted: 2025-07-30